Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)

    Predicts survival based on clinical and laboratory data in metastatic RCC patients.
    Favorite
    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with mRCC being considered for clinical trial enrollment.

    In chart reviews the MKCC/Motzer score retrospectively placed clinical trial subjects from the 1970s-1990s with metastatic renal cell carcinoma (mRCC) into three groups: poor, intermediate, and favorable survival. There are no successful validations (later studies confirmed some predictors but not others), and the score has not been applied successfully to patients in common practice or those receiving modern targeted therapies such as sunitinib.

    • Most widely used prognostic algorithm for metastatic RCC.
    • Originally created in 1999, new inputs were added in 2002 (treatment with interferon alpha) and 2004 (previously failed cytokine therapy).
    • Validated in multiple patient cohorts. Externally validated at the Cleveland Clinic.
    • Limitations: only for metastatic RCC.

    There are no validated scoring systems for predicting survival in mRCC. Using a score may help sketch categories of survival time better than clinical judgment alone.

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    The Motzer score is often used for mRCC, commonly for selecting patients to enroll in clinical trials. The score retrospectively identified some variables associated with survival, which may ultimately help predict outcomes.

    Management

    We are unaware of validated management algorithms using the score.

    Critical Actions

    The Motzer score is not known to be accurate for individual survival prediction and should be considered a general guide rather than a reliable predictor.

    Dr. Robert J. Motzer

    About the Creator

    Robert J. Motzer, MD, is a medical oncologist at Memorial Sloan Kettering Cancer Center. He received the Career Development Award from the National Institutes of Health and the Schonfeld Award from the Kidney Cancer Association. Dr. Motzer’s research focuses on renal cell carcinoma, germ-cell tumors, and bone marrow and blood cell transplantation.

    To view Dr. Robert J. Motzer's publications, visit PubMed